What Myoxan Treats: Main Uses and Benefits

Myoxan is applied in the symptomatic treatment of pathological muscle hypertonicity, which manifests as spasticity in adults. This means the medication is commonly used across conditions characterized by symptoms of increased neurological or muscular activity that create noticeable physiological strain.

The therapeutic focus is on persistent muscle rigidity and stiffness resulting from central nervous system damage, such as post-stroke spasticity. The medication may also be applied in addressing acute, painful involuntary muscle spasms, like those in the back, when supportive symptom management is appropriate. The medication is considered relevant for managing symptoms related to both chronic stiffness and acute episodes when patients experience significant muscle tension.

“The medication supports patients during difficult episodes by easing distress and assists with maintaining a sense of functional stability during rehabilitation, which is a key therapeutic aim.”

The medication is applied to address symptoms related to excessive muscle tension, and this therapeutic support assists with supporting alertness. This quality helps patients during difficult episodes by easing distress while maintaining cognitive engagement, which supports general well-being during symptomatic phases.

Quick Fact: Relief for Persistent Stiffness
Myoxan assists with managing chronic muscle rigidity in adults, notably in the context of post-stroke rehabilitation, and contributes to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. European Medicines Agency (EMA) on Tolperisone

Regulatory documents explicitly define the patient populations who may and must not use Myoxan (tolperisone). This information dictates eligibility based on age, specific medical condition, hypersensitivity history, and dosage form.

Eligibility Constraints

Category	Allowed Population (as per official label)
Age	Adults only.
Condition	Treatment of post-stroke spasticity (muscle stiffness) only.
Formulation	Only the oral formulation (e.g., tablets) may be used; injectable forms have had their marketing authorizations revoked in some regions.

Contraindicated Populations (Must Not Use)

Category	Contraindication (Exclusion)
Allergy	Patients with a known hypersensitivity (allergy) to the active substance (tolperisone) or any other component in the medicine.
Other	Use for any condition other than post-stroke spasticity is generally not recommended in adults, based on official regulatory review.

The official regulatory profile strictly limits the use of Myoxan to adults requiring treatment for the singular, specified condition of post-stroke spasticity. Use is explicitly contraindicated for any individual with an allergy to the product components. Furthermore, only the oral formulation is considered eligible for use, as the injectable form is no longer permitted by some regulatory bodies.

Interactions with other medicines and products

The interaction profile of Myoxan (Tolperisone hydrochloride) is defined by its effects on drug metabolism and potential pharmacodynamic potentiation, as documented in official regulatory sources. No medicines are formally documented as strictly contraindicated for co-administration due to interaction risk.

Pharmacokinetic Interactions

Myoxan is documented as an inhibitor of the CYP2D6 enzyme, which can increase the blood levels (exposure) of co-administered medicines that are metabolized primarily by this pathway. Specific examples listed in regulatory documents include certain antidepressants (venlafaxine, desipramine), antipsychotics (thioridazine, perphenazine), and beta-blockers (metoprolol, nebivolol).

Pharmacodynamic Effects

Co-administration with other Centrally Acting Muscle Relaxants may lead to additive central effects. The medication is also documented to potentiate the effect of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as niflumic acid. For these combinations, regulatory documents note the potential need for dose consideration of the co-administered drug.

Product Interactions and Constraints

The bioavailability of Myoxan is significantly decreased when taken without food, resulting in the official regulatory recommendation for consistent administration in relation to meals. However, regulatory data explicitly state that Myoxan does not influence the central nervous system effects of alcohol.

Myoxan (Tolperisone hydrochloride) is a centrally acting compound that modulates neuronal excitability primarily within the central nervous system, including the spinal cord and brainstem. Its principal mechanism involves the direct interaction with and blockade of voltage-gated ion channels. Specifically, Myoxan is an inhibitor of voltage-gated sodium channels and, to a lesser extent, N-type voltage-gated calcium channels.

The resulting reduction in sodium and calcium ion influx decreases neuronal depolarization and suppresses the generation of action potentials in presynaptic neurons. This mechanistic cascade leads to a reduction in the release of excitatory neurotransmitters. At the systemic level, this action dampens the exaggerated signal transmission pathways responsible for abnormal muscle activation. Furthermore, Myoxan exhibits activity as an inhibitor of both monosynaptic and polysynaptic spinal reflexes, limiting the coordination and propagation of signals within the spinal cord. These actions collectively modulate motor control pathways.

How Myoxan is Used: Administration Overview

Myoxan (Tolperisone hydrochloride) is used in clinical practice according to specific protocols focusing strictly on administration and dosing. These guidelines define the approved forms, routes, and schedules for the medicine.

---

Approved Routes and Dosage Forms

Myoxan is available as a film-coated tablet for oral administration and as a solution for injection. The injectable form is intended for intramuscular (IM) or intravenous (IV) use, although in some regions, the injectable use has been restricted or withdrawn due to safety profile considerations.

Standard Adult Dosing and Frequency

The oral dosing regimen for adults follows a standardized schedule, with adjustments based on individual patient needs and tolerance:

Parameter	Standard Adult Oral Regimen
Starting/Maintenance Dose	50 mg to 150 mg per dose
Dosing Frequency	Three times daily (TID)
Maximum Daily Dose	Up to 600 mg per day

Key Administration Instructions

The proper intake of the oral tablet is critical for bioavailability. Tablets must be taken during or immediately after meals with a glass of water, as food significantly enhances the absorption of the active ingredient. Tablets must be swallowed whole.

Population-Specific Adjustments

Established protocols mandate dose reductions for specific populations. The dosage must be reduced in patients with known hepatic or renal impairment. Although use in children is sometimes described based on weight (mg/kg), some manufacturers advise against use in individuals under 18 years old due to limited safety data. Doses in older adults may also require reduction.

Research Evidence / Overview of Studies for Myoxan

---

Evidence for Chronic Muscle Hypertonicity (Spasticity)

This section will summarize the available evidence structure, focusing on Randomized Controlled Trials (RCTs) and other studies that examined Myoxan for persistent muscle rigidity and stiffness, particularly in the context of post-stroke spasticity in adults. The focus will be on the study design and the specific outcomes, like muscle tone and functional capabilities, that were measured.

Research has explored the management of increased muscle tension and rigidity often seen after a stroke, which is a condition characterized by functional limitations. Studies primarily involved controlled trials where adults were observed over defined time intervals, typically ranging from 6 to 12 weeks. Researchers examined outcomes related to physical discomfort by measuring muscle tone using standard scales like the Modified Ashworth Scale (mAS). They also explored functional capabilities using scales such as the Barthel Index (BI) to see whether outcomes were observed in the treatment group.

The body of available evidence for this use is structurally classified as Moderate.

---

Evidence for Acute, Painful Muscle Spasm

This section will outline the research structure, primarily the short-term Randomized Controlled Trials (RCTs), conducted to assess Myoxan's role in the symptomatic treatment of acute involuntary muscle spasms, such as those experienced in the back. The summary will detail the types of scales used to measure pain and functional improvement during these acute episodes.

Myoxan was studied for its role in conditions involving periods of heightened symptoms, such as acute, painful muscle spasms. These research scenarios involved short-term trials, often lasting 7 to 14 days. The studies explored episodic changes by monitoring patient-reported outcomes describing perceived discomfort. Reports noted patterns in cognitive state, where a non-sedating profile was observed in the Myoxan group compared to other muscle relaxants in some studies.

---

Long-Term Studies and Follow-Up Duration

Across both spasticity and acute spasm research scenarios, the follow-up durations were limited. For chronic conditions, studies monitored responses for a maximum of about 12 weeks. The long-term effects are not fully established, and the most consistent limitation noted is the limited information for long-term outcomes due to short follow-up durations across most studies. The research highlights patterns observed in the short-term and intermediate periods, but also describes the current data limitations.

Common questions about Myoxan (FAQ)

---

Q: Does this medication make you sleepy or affect my ability to drive?

Official product information indicates that this medication may cause dizziness or drowsiness. Because of this potential effect, patients taking Myoxan should be monitored for impaired mental or physical abilities. Patients should discuss performing potentially hazardous activities, like driving a car or operating heavy machinery, with their healthcare provider if these effects occur.

---

Q: Can I drink alcohol while taking this medicine?

Regulatory documents state that Myoxan is contraindicated for use in patients with known alcoholism or those who report drinking more than three alcoholic beverages per day. Official prescribing information also includes warnings to avoid chronic or acute excessive alcohol use while on this medication. This is due to an increased risk of serious side effects, such as pancreatitis, when combined with alcohol.

---

Q: How should I store this medication?

According to official regulatory instructions, Myoxan should be stored in the container it was provided in, tightly closed, and kept out of the reach of children. Official storage instructions indicate the medication should be stored at room temperature, away from excess heat and moisture.

---

Q: Can I take this medicine for migraines?

The official regulatory documents state that Myoxan is indicated only for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in adults. The indication is specifically for this condition, and the regulatory label does not include the treatment of migraines.

---

Q: Is it safe for long-term use?

Official labeling mentions that clinical trials for Myoxan included a safety assessment period lasting up to 52 weeks. Prescribing information also advises healthcare providers to periodically assess the need for continued treatment in their patients, as the duration of use should be determined by a healthcare professional.

---

Q: Can children 2 years old use it?

Myoxan is indicated for use in adults who have Irritable Bowel Syndrome with Diarrhea (IBS-D). The safety and effectiveness of this medication have not been established for use in pediatric patients, including children 2 years old, according to the official regulatory documents.

The official labeling for Myoxan (tolperisone) specifies strict conditions for storage to maintain the product's 24-month stability. The film-coated tablets must be stored at a temperature not exceeding 30 C and must be kept in the original, tightly closed package to protect them from light and moisture. A mandatory regulatory requirement is to keep the medicine out of the sight and reach of children.

Disposal must adhere to environmental regulations. Unused or expired medication should not be thrown into drains or water courses. The correct procedure is to dispose of the product in accordance with local/national regulations, often through authorized medicine take-back programs.